TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01351649

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: middle school physical activity intervention for girls
Description: Both the Girls on the Move intervention and attention control conditions will involve 2 components: face-to-face (individual) counseling sessions with a school nurse and an after-school (group) program. The intervention for the attention control group will not address physical activity. Both groups will respond to questionnaires at 0 (baseline) and 6 mos. Our Girls on the Move intervention is designed to help girls achieve physical activity recommendations (≥ 60 min. ≥ 5 days/wk.). The motivational, individually tailored counseling sessions with a school nurse and after-school physical activity club (3-5 times a wk. for 6 mos.) are designed to positively influence all cognitive and affective mediating variables of the Health Promotion Model.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: middle school physical activity intervention for girls
Description: Both the Girls on the Move intervention and attention control conditions will involve 2 components: face-to-face (individual) counseling sessions with a school nurse and an after-school (group) program. The intervention for the attention control group will not address physical activity. Both groups will respond to questionnaires at 0 (baseline) and 6 mos. Our Girls on the Move intervention is designed to help girls achieve physical activity recommendations (≥ 60 min. ≥ 5 days/wk.). The motivational, individually tailored counseling sessions with a school nurse and after-school physical activity club (3-5 times a wk. for 6 mos.) are designed to positively influence all cognitive and affective mediating variables of the Health Promotion Model.
Study: NCT01786161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin continuous infusion
Description: Vancomycin 24 hour intravenous continuous infusion
Study: NCT00814372

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: greater than or equal to 1500 mg/kg day
Study: NCT01737112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-3PRGD2
Description: For patients in suspicion of lung cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
Study: NCT03110432

Intervention type: DRUG
Intervention: PCSK9 Inhibitor [EPC]
Description: drug use according to the respective product labelling

Intervention type: DRUG
Intervention: Standard lipid lowering therapy
Description: drug use according to the respective product labelling
Study: NCT01750268

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical Management Counseling
Description: Brief alcohol and medication counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Management Counseling
Description: Brief alcohol and medication counseling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Experimental medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT00966940

Intervention type: DRUG
Group type: OTHER
Intervention: Travoprost 0.004% ophthalmic solution (TRAVATAN)
Description: One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
Study: NCT00494286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abused-focused cognitive behavioral therapy (AF-CBT)
Description: Practitioners will be randomly assigned to provide the AF-CBT treatment for 3 to 6 months. Patient participants will continue to see their regular practitioner, but will receive AF-CBT at treatment visits. Practitioners who are assigned to AF-CBT will first receive training in the treatment method. The training curriculum will include a published treatment book, intensive training sessions, which will occur weekly for 8 hours over 4 weeks, handouts that illustrate key therapeutic information and exercises, and ongoing case consultation reviews for 5 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: This condition consists of those practitioners in each agency who will not receive study training in AF-CBT. These practitioners will simply provide services as available within their agencies.
Study: NCT00128908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Continuous Highly Active Antiretroviral Therapy (HAART)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapidly Cycled HAART
Study: NCT02459132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval exercise
Description: See arm/group description
Study: NCT00788632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient educational DVD and brochure
Description: Construct a tailored direct-to-patient intervention to educate and activate older women about osteoporosis testing and treatment and aimed at improving patient-provider communication and closing the loop between knowledge communication and action. The intervention will include risk assessment, will be delivered through culturally/ethnically tailored story-telling, and will be mailed-out as both a paper copy (Booklet) and an interactive DVD (allowing the patient to use the delivery mediums they are most comfortable with). A follow-up brochure will be sent as a booster.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physician web modules
Description: Web based osteoporosis continuing medical education (CME) materials

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: System
Description: Create a practice redesign strategy to alert patients that they should receive a BMD test and provide them with direct patient access to schedule their own test
Study: NCT03287375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC
Study: NCT01786161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin intermittent dosing interval
Description: Vancomycin intravenous infusion at rate 1000mg/hr
Study: NCT02705365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: One to one patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
Study: NCT02559479

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss interventional study with a low-calorie 18%-protein diet
Study: NCT00966940

Intervention type: DRUG
Group type: OTHER
Intervention: Tafluprost 0.0015% ophthalmic solution
Description: One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration

Intervention type: DRUG
Group type: OTHER
Intervention: Tafluprost 0.0015% ophthalmic solution
Description: One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
Study: NCT02559479

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss interventional study with a low-calorie 35%-protein diet
Study: NCT03971799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD33CART autologous
Description: The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by autologous CD33CART infusion:~LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).~Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD33CART allogeneic
Description: The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by allogeneic CD33CART infusion:~LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).~Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable.
Study: NCT00611091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic delivery of enhanced discharge information to the ambulatory physician
Description: Follow-up appointment needs/plans

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic delivery of enhanced discharge information to the ambulatory physician
Description: Laboratory follow-up needs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic delivery of enhanced discharge information to the ambulatory physician
Description: New medications
Study: NCT04208815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk Polar Lipids
Description: Effects of the addition of 5 g of milk polar lipids to 20 g milk fat.
Study: NCT02577289

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)
Description: • The sinus cavity will be augmented with bone graft ( Nano crystalline hydroxyapatite)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)
Description: platelet rich fibrin (PRF) as sole grafting material in created space (PRF)
Study: NCT04208815

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Milk Fat
Description: Effects of the addition of 20 g milk fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk Fat
Description: Effects of the addition of 20 g milk fat.
Study: NCT00995332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine, all-trans retinoic acid, valproic acid
Description: ATRA: 22.5 mg/m2 twice daily for 2 weeks every third month Valproic acid: continuous therapy, dosage guided by serum levels Cytarabine: 10 mg/m2 once daily for up to 10 days every third month
Study: NCT02903927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of CT LUCIA IOL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of Acrysof IQ SN60WF IOL
Study: NCT02755233

Intervention type: OTHER
Intervention: Pulmonary Function
Description: Spirometry and DLCO were measured according to performance standards based on the statements from the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Values of DLCO were adjusted for the patient's current hemoglobin value, and the patients were asked to withhold cigarette smoking at least four hours before pulmonary function testing. Lung volumes and DLCO were measured with a commercial ZAN300 CO Diffusion system (nSpire Health GmbH, Oberthulba, Germany)
Study: NCT03828656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NightWare Therapeutic System
Description: A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
Study: NCT00303316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV//PRP~T combined vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV//PRP~T combined vaccine
Description: 0.5 mL, Intramuscular
Study: NCT03508362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fRMI)
Description: Acquisition of a functional MRI on the sub thalamic nucleus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging (fRMI)
Description: Acquisition of a functional MRI on the sub thalamic nucleus
Study: NCT01925742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated prenatal screening for Down's syndrome
Description: Analysis of several serum biochemical markers, and fetal nuchal translucency by ultrasound, with computation of an individual risk of fetal aneuploidy.
Study: NCT02705365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care during the study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
Study: NCT02385773

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PTM202
Description: Administration of study nutritional product once per day for 3 days starting immediately after enrollment

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Enfamil Puramino
Description: Administration of 30 ml of Enfamil Puramino as placebo once per day for 3 days starting immediately after enrollment
Study: NCT03869619

Intervention type: OTHER
Intervention: Real-life epidemiological platform of lymphoma in France
Description: The REALYSA database will be described with the following characteristics:~* Number of patients included per month in total and according to subtype of lymphoma~* Number of patients in each region in total and according to subtype of lymphoma
Study: NCT01868737

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Lactobacillus rhamnosus GG and Bifidobacterium infantis'

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Lactobacillus rhamnosus GG and Bifidobacterium infantis'

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MCT oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MCT oil
Study: NCT06181188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will receive a combination of ketamine and midazolam for conscious sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Patients will receive 1mg of midazolam regardless of which arm they are in and my be given 1mg doses for added sedation as needed every 3-5 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patients will receive 1mg of midazolam regardless of which arm they are in and my be given 1mg doses for added sedation as needed every 3-5 minutes
Study: NCT03696121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin Injection
Description: Single dose 20 micrograms in 50ml Normal Saline as intravenous injection infused over 20 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Single dose 50ml Normal Saline as intravenous injection infused over 20 minutes
Study: NCT01073618

Intervention type: DRUG
Intervention: voriconazole IV
Description: 6 mg/kg iv q 12 hours (loading) then maintenance
Study: NCT02328664

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Flexible sigmoidoscopy or colonoscopy
Description: Depending on the localization of the scar of the malignant polyp, either a flexible sigmoidoscopy or colonoscopy will be done to take biopsies from the polypectomy scar.
Study: NCT02057822

Intervention type: PROCEDURE
Intervention: Cytokins assay in tears
Study: NCT01925742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated prenatal screening for Down's syndrome
Description: Analysis of several serum biochemical markers, and fetal nuchal translucency by ultrasound, with computation of an individual risk of fetal aneuploidy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum QUAD Assay for aneuploidy screening
Description: Series of biochemical markers with results integrated into a computational estimate of risk of fetal aneuploidy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum QUAD Assay for aneuploidy screening
Description: Series of biochemical markers with results integrated into a computational estimate of risk of fetal aneuploidy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semiconductor MPSS NIPT assay using ccfDNA in maternal blood
Description: Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using a targeted NIPT assay.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semiconductor MPSS NIPT assay using ccfDNA in maternal blood
Description: Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using a targeted NIPT assay.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical-based MPSS NIPT assay using ccfDNA in maternal blood
Description: Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using an un-targeted NIPT assay.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical-based MPSS NIPT assay using ccfDNA in maternal blood
Description: Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using an un-targeted NIPT assay.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harmony™ Test (Ariosa Diagnostics)
Description: Test that is commercially available (Ariosa Diagnostics). (will be used for benchmarking purposes in a subset of each arm)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harmony™ Test (Ariosa Diagnostics)
Description: Test that is commercially available (Ariosa Diagnostics). (will be used for benchmarking purposes in a subset of each arm)
Study: NCT04514146

Intervention type: OTHER
Intervention: Water-only fasting
Description: In-patient water-only fasting for at least 10 days followed by at least 5 days of refeeding
Study: NCT00962182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAN1
Description: 3-4 capsules/day at meals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo enzyme
Description: 3-4 capsules/day at meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAN1+gluten
Description: 3-4 capsules/day at meals plus 500 mg gluten b.i.d
Study: NCT00139490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education Program
Description: The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Group
Description: The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Usual Care
Study: NCT02761265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Description: Surgery to correct spinal deformity

Intervention type: OTHER
Group type: OTHER
Intervention: None (Asymptomatic group)
Description: Gait and balance testing performed, no treatment in this asymptomatic group
Study: NCT02586545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared care
Study: NCT00420290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: kineret
Description: 100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
Study: NCT03910582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: personalized frozen-thawed embryo transfer
Description: The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: routine frozen-thawed embryo transfer
Description: The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
Study: NCT04014101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Apatinib is a selective VEGFR2 inhibitor.
Study: NCT02760784

Intervention type: BEHAVIORAL
Intervention: Early weight bearing
Description: The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
Study: NCT01808014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nefopam
Description: The chief investigator prepared the medications according to the selected randomized table, and investigators who were not involved in medication preparation recorded the pain and prevalence of complications in study subjects. The double-blind restriction was lifted if the patient withdrew from the study, and the next patient was classified into a group while blinded by using the randomized table.Intramuscular midazolam 0.05 mg/kg was administered as a premedication, and then a blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room.
Study: NCT02805569

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: articulating stylet
Description: patient who intubated with articulating stylet

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional stylet
Description: patient who intubated with conventional stylet